TransMedics Group seen as strong buy with growth driven by new organ transport tech and European expansion.

TransMedics Group is rated a strong buy due to its leading technology in organ transport, particularly its OCS and NOP programs which outperform the sector. The stock trades at a reasonable valuation compared to its growth forecast of 20%-25% and peers in medical technology. Key growth drivers include the upcoming OCS Kidney launch expected in late 2026 or early 2027 and expansion into European markets like Italy, which could significantly increase sales volume. Short-term risks involve margin pressure from rising oil prices and temporary profit margin dips due to ongoing clinical trials and development of the OCS Kidney program.